Patents by Inventor Naosuke KAMEI

Naosuke KAMEI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220313741
    Abstract: A method for treating or repairing osteochondral damage in a subject in need thereof, including administering to the subject a cell preparation comprising pluripotent stem cells positive for SSEA-3 isolated from a body mesenchymal tissue or cultured mesenchymal cells. The pluripotent stem cells have all of the following properties: (i) CD105-positivity; (ii) low or absent telomerase activity; (iii) having ability to differentiate into any of three germ layers; (iv) absence of demonstration of neoplastic proliferation; and (v) self-renewal ability. The pluripotent stem cells are administered at 1×103 cells to 2×107 cells as individual.
    Type: Application
    Filed: June 21, 2022
    Publication date: October 6, 2022
    Applicants: Hiroshima University, TOHOKU UNIVERSITY
    Inventors: Naosuke KAMEI, Mari DEZAWA, Mitsuo OCHI
  • Publication number: 20220105355
    Abstract: Provided is a technique that makes it possible to efficiently guide a magnetized cell by application of a magnetic field. The magnetized cell contains iron oxide, the magnetized cell containing iron, derived from the iron oxide, in an amount of not less than 35 pg/cell.
    Type: Application
    Filed: September 22, 2021
    Publication date: April 7, 2022
    Inventors: Naosuke KAMEI, Mitsuo OCHI, Yoshikazu TANAKA, Naotaka HIRAMI
  • Publication number: 20200237828
    Abstract: Multilineage-differentiating stress enduring (Muse) cells are stage-specific embryonic antigen-3 (SSEA-3) positive cells that exist in mesenchymal stem cell (MSC) populations. Muse cells have the pluripotency to differentiate into all germ layers as embryonic stem cells. The purpose of the present study is to investigate the efficacy of Muse cell transplantation for repairing osteochondral defects. Muse cells were isolated from human bone marrow MSCs. As osteochondral defects, the patellar grooves of immunodeficient rats were injured. Next, cells were injected into the mice so that the animals were divided into the following 3 groups: a control group to which PBS was injected; a non-Muse group to which 5×104 SSEA-3 negative non-Muse cells were injected; and a Muse group to which 5×104 SSEA-3 positive Muse cells were injected.
    Type: Application
    Filed: October 17, 2018
    Publication date: July 30, 2020
    Applicants: HIROSHIMA UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Naosuke KAMEI, Mari DEZAWA, Mitsuo OCHI